Metabolomics: A novel approach to early and noninvasive prostate cancer detection

Korean Journal of Urology

Volumn 52, Issue 2, 2011, Pages 79-89

  Roberts, Matthew J ^a   Schirra, Horst J ^b   Lavin, Martin F ^a   Gardiner, Robert A ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Biological markers; Detection; Metabolomics; Prostatic neoplasms

Indexed keywords

SARCOSINE;

CANCER DIAGNOSIS; HUMAN; METABOLOMICS; PROSTATE CANCER; PROSTATE FLUID; REVIEW;

EID: 79952502199     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.2.79     Document Type: Review

References (100)

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-91. (Pubitemid 44384305)
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Marugame T, Mizuno S. Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol 2005; 35:690-1.
4. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-45. (Pubitemid 40467547)
5. Yang SY, Adelstein J, Kassis AI. Putative molecular signatures for the imaging of prostate cancer. Expert Rev Mol Diagn 2010;10:65-74.
6. Narain V, Cher ML, Wood DP Jr. Prostate cancer diagnosis, staging and survival. Cancer Metastasis Rev 2002;21:17-27. (Pubitemid 35205191)
7. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evi dence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:192-9.
8. Crawford ED. PSA testing: what is the use? Lancet 2005;365: 1447-9.
9. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
10. Pienta KJ. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology 2009;73(5 Suppl): S11-20.
11. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
12. Barry MJ. Screening for prostate cancer - the controversy that refuses to die. N Engl J Med 2009;360:1351-4.
13. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2008;11:112-20. (Pubitemid 351676597)
14. Veltri RW, Miller MC, O'dowd GJ, Partin AW. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 2002;60(4 Suppl 1):47-52.
15. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006;97(Suppl 2):3-6. (Pubitemid 43356987)
16. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9:83-93. (Pubitemid 29265524)
17. Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, et al. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol 2007;177:1736-40. (Pubitemid 46560651)
18. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008;68:620-8. (Pubitemid 351614640)
19. DeFeo EM, Cheng LL. Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol Cancer Res Treat 2010;9:381-91.
20. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53. (Pubitemid 46579693)
21. Clarke RA, Schirra HJ, Catto JW, Lavin MF, Gardiner RA. Markers for detection of prostate cancer. Cancers 2010;2:1125-54.
22. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
23. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-9.
24. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006;5:17.
25. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004;4:551-61. (Pubitemid 38868624)
26. Abate-Shen C, Shen MM. Diagnostics: the prostate-cancer metabolome. Nature 2009;457:799-800.
27. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009;15: 431-40.
28. Serkova NJ, Spratlin JL, Eckhardt SG. NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther 2007;9:572-85. (Pubitemid 350179097)
29. Costello LC, Franklin RB. Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem. Prostate Cancer Prostatic Dis 2009;12:17-24.
30. Teahan O, Bevan CL, Waxman J, Keun HC. Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol 2010;Epub ahead of print
31. Lynch MJ, Masters J, Pryor JP, Lindon JC, Spraul M, Foxall PJ, et al. Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J Pharm Biomed Anal 1994;12:5-19. (Pubitemid 24073763)
32. Liney GP, Turnbull LW, Lowry M, Turnbull LS, Knowles AJ, Horsman A. In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging 1997;15:1177-86.
33. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
34. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59:10-6. (Pubitemid 43076233)
35. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Lisi D, Osimani M, et al. Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest 2010;28:424-32.
36. Noworolski SM, Vigneron DB, Chen AP, Kurhanewicz J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging 2008;26:1071-80.
37. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005;65:3030-4. (Pubitemid 40524579)
38. Serkova NJ, Freund AS, Brown JL, Kominsky DJ. Use of the 1-mm micro-probe for metabolic analysis on small volume biological samples. J Cell Mol Med 2009;13:1933-41.
39. Costello LC, Franklin RB, Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 1999;38:237-45. (Pubitemid 29054940)
40. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006;7:1109-23. (Pubitemid 44644788)
41. Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease. Prostate 1997;30:248-55. (Pubitemid 27172836)
42. Cooper JF, Imfeld H. The role of citric acid in the physiology of the prostate: a preliminary report. J Urol 1959;81:157-64.
43. Averna TA, Kline EE, Smith AY, Sillerud LO. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. J Urol 2005;173:433-8.
44. Kline EE, Treat EG, Averna TA, Davis MS, Smith AY, Sillerud LO. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. J Urol 2006;176:2274-9. (Pubitemid 44633142)
45. Zaichick VY, Sviridova TV, Zaichick SV. Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma and cancer. Int Urol Nephrol 1996;28:687-94. (Pubitemid 27110256)
46. Cooper JF, Farid I. The role of citric acid in the physiology of the prostate. 3. lactate/citrate ratios in benign and malignant prostatic homogenates as an index of prostatic malignancy. J Urol 1964;92:533-6.
47. Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 1993;29:149-57. (Pubitemid 23078507)
48. Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol 1993; 150:2019-24. (Pubitemid 24350856)
49. Mintz A, Wang L, Ponde DE. Comparison of radiolabeled choline and ethanolamine as probe for cancer detection. Cancer Biol Ther 2008;7:742-7.
50. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12:413-39. (Pubitemid 30016999)
51. van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, et al. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA 2008;21:435-42.
52. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 2008;60:510-6.
53. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, et al. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate 2010;70:1692-700.
54. Stenman K, Hauksson JB, Gröbner G, Stattin P, Bergh A, Riklund K. Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy. MAGMA 2009;22: 327-31.
55. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006;55: 1257-64. (Pubitemid 43856762)
56. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000;2:166-89. (Pubitemid 30123187)
57. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003;50:944-54. (Pubitemid 37356574)
58. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008;102:446-51. (Pubitemid 352032836)
59. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Radiology 2008;246:480-8.
60. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 2007;245:507-16. (Pubitemid 47612533)
61. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 2008;60:33-40. (Pubitemid 351956607)
62. Wu CL, Jordan KW, Ratai EM, Sheng J, Adkins CB, Defeo EM, et al. Metabolomic imaging for human prostate cancer detection. Sci Transl Med 2010;2:16ra8.
63. Maxeiner A, Adkins CB, Zhang Y, Taupitz M, Halpern EF, McDougal WS, et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate 2010;70:710-7.
64. Kavanagh JP, Darby C, Costello CB. The response of seven prostatic fluid components to prostatic disease. Int J Androl 1982;5:487-96. (Pubitemid 12001744)
65. Menard C, Smith IC, Somorjai RL, Leboldus L, Patel R, Littman C, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 2001;50:317-23. (Pubitemid 32472261)
66. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, et al. Time-dependent effects of hormone- deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001;46:49-57. (Pubitemid 32592138)
67. Fass L. Imaging and cancer: a review. Mol Oncol 2008;2:115-52.
68. Kurhanewicz J, Vigneron DB. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am 2008;16:697-710.
69. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen AC, et al. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features-initial experience. Radiology 2007;242:483-9. (Pubitemid 46146201)
70. Takyi EE, Fuller DJ, Donaldson LJ, Thomas GH. Deoxyribonucleic acid and polyamine synthesis in rat ventral prostrate. Effects of age of the intact rat and androgen stimulation of the castrated rat with testosterone, 5 alpha-dihydrotestosterone and 5 alpha-androstane-3 beta, 17 beta-diol. Biochem J 1977; 162:87-97.
71. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451-63. (Pubitemid 35167879)
72. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology 1999;213:473-80. (Pubitemid 29510595)
73. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-8. (Pubitemid 29510596)
74. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5. (Pubitemid 28270113)
75. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23. (Pubitemid 350234152)
76. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273-80. (Pubitemid 34640843)
77. Kirikae M, Diksic M, Yamamoto YL. Quantitative measurements of regional glucose utilization and rate of valine incorporation into proteins by double-tracer autoradiography in the rat brain tumor model. J Cereb Blood Flow Metab 1989;9:87-95. (Pubitemid 19053439)
78. Ishiwata K, Kubota K, Murakami M, Kubota R, Senda M. A comparative study on protein incorporation of L-[methyl-3H]methio nine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol 1993;20:895-9.
79. Anderson RU, Fair WR. Physical and chemical determinations of prostatic secretion in benign hyperplasia, prostatitis, and adenocarcinoma. Invest Urol 1976;14:137-40. (Pubitemid 8002347)
80. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000;10:153-9. (Pubitemid 30397433)
81. García-Segura JM, Sánchez-Chapado M, Ibarburen C, Viaño J, Angulo JC, González J, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magn Reson Imaging 1999;17: 755-65.
82. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010;47:282.
83. Schalken JA. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 2010;58:19-20.
84. Stephan C, Jentzmik F, Jung K. Reply from Authors re: Jack A. Schalken. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 2010;58:19-20. Eur Urol 2010;58:20-1
85. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur Urol 2010;58:e29-30.
86. Jentzmik F, Stephan C, Jung K. Reply to Arun Sreekumar, Laila M. Poisson, Thekkelnaycke M. Rajendiran, et al.'s Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12-8. Eur Urol 2010;58: e31-2
87. Hewavitharana AK. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur Urol 2010;58:e39-40.
88. Jentzmik F, Stephan C, Jung K. Reply to Amitha K Hewavitharana's Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine After Digital Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12-8. Eur Urol 2010;58: e41-2.
89. Colleselli D, Stenzl A, Schwentner C. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010; 58:12-8. Eur Urol 2010.
90. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.
91. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011;185:706-11.
92. Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat 2004;3:591-8. (Pubitemid 40023549)
93. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, et al. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radio-sensitizer. Mol Ther 2009;17:430-8.
94. Umbehr M, Bachmann LM, Held U, Kessler TM, Sulser T, Weishaupt D, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 2009;55:575-90.
95. Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett 2001; 494:112-6. (Pubitemid 32289382)
96. Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging 2009;8:56-64.
97. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995;45:459-66.
98. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997;17:1455-60.
99. Kumar R, Nayyar R, Kumar V, Gupta NP, Hemal AK, Jagannathan NR, et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate- specific antigen between 4 and 10 ng/ml: a follow-up study. Urology 2008;72:859-63.
100. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805. (Pubitemid 26066301)